Company Description
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.
The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds.
Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2007 |
| IPO Date | Oct 4, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Joseph Hagan |
Contact Details
Address: 4224 Campus Point Court, Suite 210 San Diego, California 92121 United States | |
| Phone | 858 202 6300 |
| Website | regulusrx.com |
Stock Details
| Ticker Symbol | RGLS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001505512 |
| CUSIP Number | 75915K309 |
| ISIN Number | US75915K3095 |
| Employer ID | 26-4738379 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph P. Hagan M.B.A. | Chief Executive Officer and Director |
| Crispina Calsada CPA | Chief Financial Officer |
| Christopher Ray Aker J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research and Development and Director |
| Daniel J. Penksa | Vice President of Finance and Controller |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations |
| Dr. Rekha Garg M.D., M.S. | Chief Medical Officer |
| Edmund Lee Ph.D. | Vice President of Translational Medicine |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2025 | SCHEDULE 13G | Filing |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Jan 30, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |